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The syndrome identified as hemophagocytic 
lymphohistiocytosis (HLH) poses a rather difficult 
challenge to the physician. HLH was initially described 
as a familial disorder,1 which was later associated 
with various genetic defects that affect the cytotoxic 
machinery of CD8+ T and NK cells,2 but it also occurs 
sporadically, usually prompted by infections, rheumatic 
disorders, or neoplasia.3 Although its diagnostic criteria 
are established, its clinical presentation overlaps with 
many different conditions, requiring an enhanced 
awareness of the attending physician in order to reach 
the diagnosis and to initiate treatment early enough.4
While the diagnostic criteria include either the 
presence of a known genetic disorder or five of a 
list of eight signs and symptoms,3 regardless of its 
presentation, the predominant pathophysiological 
feature of HLH is an overactive immune system. 
This can be inferred by the name-giving feature 
of the syndrome: hemophagocytosis, reflecting a 
hyperactive mononuclear phagocytic system, as a 
result of what can be classified as a cytokine storm.5 
Thus, one could be satisfied by a general view that this 
syndrome is another one of those where the immune 
system becomes rogue and turns against the body. 
Nonetheless, it is worth looking deeper into the known 
HLH immunopathological features and checking the 
believed pathway of its development against our 
models and assumptions about the physiology of the 
immune system.
In a sense, all data seem to point to an immune 
dysfunction that fits perfectly with what one expects. 
The genetic disorders associated with the familial forms 
of HLH are those that affect the cytotoxic machinery 
of NK and T lymphocytes, compromising the cytotoxic 
granule contents themselves or the molecules involved 
in granule exocytosis, so that in any case, the cytotoxic 
function of these cells is faulty. Furthermore, even 
in sporadic cases, the frequent precipitation of this 
syndrome by viral infections or its association with 
NK and T-cell lymphomas indicates that there, too, 
defective cell cytotoxicity may be the culprit.
Actually, after the role of perforin deficiency was 
described in familial cases of HLH,6 an experimental 
model that reproduces the human syndrome was 
developed.7 Perforin-deficient mice, when challenged 
with the lymphocytic choriomeningitis virus (LCMV), 
develop a progressive disease that leads rapidly to death 
if not treated. The mice present a disease that includes 
the major clinical, laboratory, histopathological, 
and immune features of the human HLH.7 Adding 
to the resemblance between the human disease, 
both in its familial and sporadic forms, and the 
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experimental mouse disease, is the fact that both 
are viral infection-triggered and rapidly progressive. 
From these data, an initial hypothesis about the 
pathophysiology of HLH is that it is a disease caused 
by an uncontrolled viral infection, which, maintaining 
a chronic stimulation of the immune system, would 
precipitate its derailing and, hence, the disease. This 
view is further supported by the observation that, in 
another model, mice lacking the orthologue gene of 
the human Munc13-4 (a gene involved in the cytotoxic 
granule exocytosis in NK and CD8+ cytotoxic T cells) 
develop a very similar disease, when infected by LCMV.8 
In humans, it is relevant to note that the Epstein–Barr 
virus (EBV) infection is frequently the trigger of HLH, 
both in familial and sporadic cases9 and, likewise, is a 
disease where cytotoxic CD8+ T cells have a definite 
role (already noticeable by their identification in blood 
smears as the characteristic “atypical lymphocytes”). 
So, experimental models data confirm that what could 
be inferred from clinical observation: defective cell 
cytotoxicity indeed plays a very significant role in HLH.
However, a simple explanation—lack of or 
defective cell cytotoxicity, allowing an unchecked 
viral expansion—does not explain all observations. 
It is true that in the perforin-deficiency model, an 
LCMV infection triggers the HLH-like syndrome and 
is associated with a very high viral load. However, 
this insufficient clearance of viruses is not enough to 
cause the disease. First, in the Munc13-4 orthologue 
gene deficiency, although the animals have poor cell 
cytotoxicity and are especially susceptible to the murine 
cytomegalovirus infection (MCMV), this latter disease 
does not trigger the HLH-like disease; only the LCMV 
infection does.8 Second, in the perforin deficient mice, 
treating the mice with antibodies against CD8, and 
thus causing the complete depletion of CD8+ T cells, 
protects the animals from the HLH-like syndrome,7 but 
not from a very high viremia. Indeed, when the kinetics 
of the disease in these mice was investigated, it became 
clear that it was not the viral load that prompted the 
immunological imbalance, but rather the excessive 
activation of the system.10
Moreover, pointing to a possible explanation 
for the phenomenon, in the same perforin-deficient 
animal model, the use of blocking antibodies against 
IFN-gamma also protects the animals from the 
HLH-like disease.7 Thus, the initial hypothesis should 
be modified: defective CD8+ T cells unable to 
perform their cytotoxic function effectively, allow the 
virus to overstimulate CD8+ T cells, which display a 
deregulated interferon-gamma secretion, thus driving 
the disease. This modified pathophysiological view 
is further supported by data showing that, in mice, 
the continuous injection of IFN-gamma through an 
osmotic pump is enough to cause acute cytopenias and 
hemophagocytosis,11 two distinctive features of HLH. 
In addition, both LCMV in mice and EBV in humans are 
infections that cause a vigorous IFN-gamma response, 
while MCMV infection induces hyporesponsiveness 
to IFN-gamma in macrophages,12 providing a possible 
explanation for the “virus-specificity” triggering of 
HLH-like disease in immunodeficient mice.8
Complementing the hypothesis, data from the 
perforin-deficient animal model show that, in these 
mice, the absence of the adaptor molecule, MyD88, 
protects the animals from the HLH-like disease.13 The 
MyD88 molecule is central to the transduction of 
signals from most of the Toll-like receptors and from 
the IL-1 receptor;14 thus, it is clearly involved in the 
inflammatory process and, more significantly, in the 
detection of homeostatic disequilibria within tissues. 
However, it is noteworthy that here the role of this 
molecule does not seem to be in the initial detection 
of the disequilibrium, but rather, in the response to 
an already established immune response; that is, the 
secretion of IFN-gamma by CD8+ T cells.
With these experimental observations, it is possible 
to elaborate a more detailed pathophysiological view 
of the HLH. This disease would be the consequence 
of an immune dysfunction, where the immune 
system, confronted by certain IFN-gamma-inducing 
challenges, fails to control its secretion due to a 
defective machinery of cytotoxic cells, namely NK and 
CD8+ T cells. The excessive IFN-gamma secretion, 
through a MyD88-dependent pathway, would cause 
macrophages to go rogue and further disrupt an 
already shaken physiologic balance in the host, 
prompting the HLH.
However well this proposed model explains the 
experimental data, one has to ask, does it fit the actual 
human disease? Initially, at the origin of the model, 
there is a good correlation between the genetic defects 
of mice and those found in patients with familial HLH. 
Furthermore, the explanations for the triggering of the 
disease in mice and humans coincide. But, when the 
model gets down to identifying the specific cytokine 
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responsible for the generation of the disease, the 
model starts to fail: in humans, an elevated serum 
IFN-gamma, although sometimes found, is not typical 
of HLH.15 Furthermore, in a study where the peripheral 
blood cells’ gene expression profile from healthy 
controls and from familial HLH patients was studied, 
IFN-gamma and IFN-gamma-regulated genes did 
not show up as differentially expressed.16 One could 
still argue that cytokine profiles, whether they are 
established by cytokine serum levels, by intracellular 
staining, or by gene expression profiles of circulating 
cells, are still quite distant from the in vivo reality; 
therefore, one could suggest that the deregulated 
levels of IFN-gamma, although they do not show up 
in the studies performed in humans, might still exist 
within the microenvironment where the disease is 
initiated.
Then again, one would be missing a real 
opportunity: to check and even challenge our 
understanding of the immune system. The immune 
system is very complex; it was selected to deal 
specifically with molecularly unknown challenges—the 
antigens—and it performs its function with exceptional 
efficacy. Our knowledge of the circuits that control 
this system is growing rapidly and is becoming so 
detailed that the whole picture starts to escape from 
many. In this context, the complexity of the circuits and 
their interaction requires the construction of (animal) 
models, where genes can be manipulated at will and 
hypotheses can be tested with precision. However, 
diving too quickly into the models may obscure the 
initial reason for their construction—the understanding 
of the immune system and how it interacts internally 
and with its many challenges in nature—and, for the 
physician, it may also unravel strategies to interfere 
when the immune system fails and disease ensues due 
to that failure. Then, reminding us that models are 
models and diseases are diseases, a syndrome like HLH 
is invaluable—as are autopsies and case reports—for in 
these instances, models are often insufficient and our 
relative ignorance shows up, driving us to challenge 
the models and deepen our understanding.
Specifically here, it is not the relative role of one 
or other cytokine that should cause the impact, but 
rather the role we ascribe to CD8+ T cells. These 
cells are identified as antigen-specific, HLA-restricted, 
cytotoxic cells that perform an essential role in viral 
infections and in tumor immunity. Evidence from 
this function comes from both in vitro observation 
that these cells are, indeed, able to kill specific 
targets—and this was central to unravel the role of 
the major histocompatibility antigens in restricting 
T-cell recognition of antigens,17 but also from animal 
models, where their absence allows the uncontrolled 
progression of viral infections, as happens in the 
perforin-deficient mouse, which was discussed before.
However, the role of T-cell cytotoxicity in the 
control of virus infections in humans is not so 
clear-cut. Since children with immunodeficiencies 
characterized by the absence of CD8+ T cells are 
not more susceptible to viral infections than healthy 
children,18 one must accept that either cytotoxicity in 
humans is irrelevant against viruses, or that it is not the 
CD8+ T cell but other cytotoxic cell that performs this 
function in these immunodeficient children. Actually, 
cell cytotoxicity is not an exclusive characteristic of 
CD8+ T cells—other cells can do it—but CD8+ T cells 
have the ability to specifically recognize antigens in 
the context of class I HLA molecules, therefore on the 
surface of any nucleated cell, and this seems to be 
unique to these cells. This feature leaves CD8+ T cells 
equipped to recognize and respond to the presence 
of a virus or of mutated proteins in “any” cell in the 
body—a function that would be required, in fact, in 
cells involved in the control of virus infections and 
cancer. The relevance of this function could be further 
stressed by the observation that many viruses hinder 
the expression of HLA molecules by the infected cells, 
clearly suggesting the role of these molecules in their 
control.19-21 But if cell cytotoxicity is not the pathway 
through which CD8+ T cells perform their function 
once they recognize their targets, what would it be? 
And the answer seems to be in their cytokine secretion. 
In animal models of cancer,22 viral infections,23 and 
human diseases,24,25 cytokine secretion by these cells 
appears to be the decisive, if not the main, effective 
factor. Thus, after challenging the model of HLH, 
where IFN-gamma secretion by CD8+ T cells would be 
the triggering factor, we are back to this hypothesis. 
Definitely, IFN-gamma (or cytokines) secretion is 
characteristic of CD8+ T cells and, if exaggerated, could 
prompt the derailing of the immune system.
But the question remains: how would a cytotoxic 
defect prompt a deregulated cytokine secretion? We 
have seen that the viral load, per se, a simple and 
direct possibility, does not solve this issue; hence, the 
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answer must be elsewhere. This brings to light another 
possible role of CD8+ T cells: immunoregulation. In the 
1970s and early 1980s, T cells were classified as either 
helper T cells or suppressor/cytotoxic T cells. The latter 
population included cells clearly cytotoxic—those that 
are identified today as CD8+ T cells—and others that 
were indistinguishable from the cytotoxic cells by the 
surface markers then available, but whose function 
seemed to be the specific suppression of immune 
responses. This putative T-cell population did not resist 
deeper investigations, and later on, many immune 
regulatory circuits were described, including the 
“opposing” T helper subsets and the regulatory T cells, 
which could explain much of the earlier observations of 
specific immunosupression. Nevertheless, a “revival” of 
the regulatory role for the “cytotoxic” T cells seems to 
offer a solution in the case of HLH.
Thus, the pathophysiology of HLH could be 
described as an initial challenge to the immune 
system that drives the activation of CD8+ T cells. 
Due to a genetic defect (in the familial cases), or to 
local and/or transient conditions (in sporadic cases), 
these cells fail to perform an essential (and relatively 
ignored) role: the control of their own activation. With 
uncontrolled stimulation, CD8+ T cells cause other 
cells down the pathway of the immune response, 
like macrophages, to become further active, to 
secrete other cytokines, and, thus, trigger the 
disease. Therefore, in the end, it could seem that the 
pathophysiology of HLH is solved. Yet, this is not true. 
It could be enough to remember that it remains to be 
determined how the cytotoxic machinery of cytotoxic 
T cells affects immune activation and if it does truly 
occur in patients with HLH. But the uncertainties go 
further. The main characteristics of HLH are in the 
name of the syndrome itself: hemophagocytosis, 
lymphocytosis, and histiocytosis of tissues. Though 
a possible explanation for hemophagocytosis can 
be found on the action of cytokines (IFN-gamma in 
the model), the tissue infiltration by immune cells is 
not clearly explained. What drives their movement 
towards tissues? What keeps them active therein? And 
if we keep looking at case reports and autopsies of 
patients that presented HLH, new questions and new 
challenges will appear—and, hopefully, will drive our 
investigations towards a more comprehensive view 
of its pathophysiology and a more effective way to 
diagnose and treat it.
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